The Cooper Companies, Inc. (NASDAQ:COO) Shares Acquired by Wells Fargo & Company MN

Wells Fargo & Company MN boosted its stake in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 0.7% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 315,129 shares of the medical device company’s stock after acquiring an additional 2,224 shares during the period. Wells Fargo & Company MN owned about 0.63% of Cooper Companies worth $119,258,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the stock. Lipe & Dalton increased its stake in Cooper Companies by 0.9% in the fourth quarter. Lipe & Dalton now owns 3,360 shares of the medical device company’s stock valued at $1,272,000 after purchasing an additional 30 shares during the last quarter. WD Rutherford LLC grew its position in shares of Cooper Companies by 0.4% during the fourth quarter. WD Rutherford LLC now owns 9,126 shares of the medical device company’s stock worth $3,541,000 after acquiring an additional 33 shares during the last quarter. Blue Trust Inc. grew its position in shares of Cooper Companies by 54.8% during the fourth quarter. Blue Trust Inc. now owns 96 shares of the medical device company’s stock worth $36,000 after acquiring an additional 34 shares during the last quarter. Loomis Sayles & Co. L P grew its position in shares of Cooper Companies by 26.5% during the third quarter. Loomis Sayles & Co. L P now owns 167 shares of the medical device company’s stock worth $53,000 after acquiring an additional 35 shares during the last quarter. Finally, Venturi Wealth Management LLC grew its position in shares of Cooper Companies by 30.4% during the fourth quarter. Venturi Wealth Management LLC now owns 180 shares of the medical device company’s stock worth $68,000 after acquiring an additional 42 shares during the last quarter. 24.39% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CAO Agostino Ricupati sold 54,724 shares of the stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $100.89, for a total transaction of $5,521,104.36. Following the completion of the sale, the chief accounting officer now owns 5,081 shares of the company’s stock, valued at approximately $512,622.09. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Cooper Companies news, Director Gary S. Petersmeyer sold 1,000 shares of the stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $103.51, for a total value of $103,510.00. Following the completion of the sale, the director now owns 5,668 shares of the company’s stock, valued at $586,694.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Agostino Ricupati sold 54,724 shares of the stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $100.89, for a total value of $5,521,104.36. Following the transaction, the chief accounting officer now owns 5,081 shares of the company’s stock, valued at $512,622.09. The disclosure for this sale can be found here. Corporate insiders own 2.00% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on COO. Redburn Atlantic upgraded shares of Cooper Companies from a “neutral” rating to a “buy” rating and set a $125.00 target price on the stock in a research report on Tuesday, March 19th. TheStreet lowered shares of Cooper Companies from a “b-” rating to a “c” rating in a research report on Thursday, February 29th. Stifel Nicolaus reiterated a “buy” rating and issued a $110.00 price objective (up from $105.00) on shares of Cooper Companies in a research report on Friday, March 1st. JPMorgan Chase & Co. upgraded shares of Cooper Companies from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $100.00 to $120.00 in a research report on Wednesday, March 13th. Finally, Piper Sandler lifted their price objective on shares of Cooper Companies from $110.00 to $115.00 and gave the company an “overweight” rating in a research report on Friday, March 1st. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $109.69.

Cooper Companies Price Performance

Cooper Companies stock opened at $96.60 on Thursday. The firm has a market capitalization of $19.20 billion, a PE ratio of 66.05, a P/E/G ratio of 2.45 and a beta of 0.97. The company has a quick ratio of 1.08, a current ratio of 1.86 and a debt-to-equity ratio of 0.35. The firm’s 50-day simple moving average is $95.71 and its 200 day simple moving average is $93.24. The Cooper Companies, Inc. has a 52 week low of $75.93 and a 52 week high of $104.07.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings data on Thursday, February 29th. The medical device company reported $0.85 EPS for the quarter, beating analysts’ consensus estimates of $0.78 by $0.07. Cooper Companies had a net margin of 7.93% and a return on equity of 8.79%. The company had revenue of $931.60 million during the quarter, compared to the consensus estimate of $915.93 million. During the same quarter in the prior year, the company posted $2.90 EPS. The company’s quarterly revenue was up 8.5% compared to the same quarter last year. On average, equities research analysts predict that The Cooper Companies, Inc. will post 3.5 EPS for the current fiscal year.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.